Beacon Financial Advisory LLC Purchases 7,074 Shares of Pfizer Inc. (NYSE:PFE)

Beacon Financial Advisory LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 17.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 48,437 shares of the biopharmaceutical company’s stock after buying an additional 7,074 shares during the period. Beacon Financial Advisory LLC’s holdings in Pfizer were worth $1,227,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Beam Wealth Advisors Inc. raised its stake in shares of Pfizer by 1.5% in the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock worth $728,000 after purchasing an additional 401 shares during the last quarter. Providence Capital Advisors LLC boosted its position in Pfizer by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock valued at $3,034,000 after buying an additional 409 shares during the last quarter. Donaldson Capital Management LLC raised its position in Pfizer by 1.2% during the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock worth $947,000 after buying an additional 410 shares during the last quarter. Noesis Capital Mangement Corp lifted its stake in Pfizer by 2.6% during the 4th quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company’s stock valued at $434,000 after acquiring an additional 413 shares during the period. Finally, First Command Advisory Services Inc. boosted its holdings in shares of Pfizer by 2.5% in the 4th quarter. First Command Advisory Services Inc. now owns 17,479 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 418 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of several recent research reports. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Finally, Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Trading Up 0.2%

Shares of PFE stock opened at $24.30 on Friday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a market cap of $138.18 billion, a price-to-earnings ratio of 17.61, a PEG ratio of 0.88 and a beta of 0.57. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The stock has a 50 day simple moving average of $23.42 and a 200-day simple moving average of $24.85.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the firm earned $0.82 EPS. The firm’s revenue was down 7.8% compared to the same quarter last year. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.08%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s payout ratio is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.